JP7712060B2 - 新規ｖｅｇｆｒ－２ターゲット免疫療法アプローチ - Google Patents

新規ｖｅｇｆｒ－２ターゲット免疫療法アプローチ

Info

Publication number
JP7712060B2
JP7712060B2 JP2019544614A JP2019544614A JP7712060B2 JP 7712060 B2 JP7712060 B2 JP 7712060B2 JP 2019544614 A JP2019544614 A JP 2019544614A JP 2019544614 A JP2019544614 A JP 2019544614A JP 7712060 B2 JP7712060 B2 JP 7712060B2
Authority
JP
Japan
Prior art keywords
cancer
protein
salmonella
pharmaceutical composition
vegfr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019544614A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020507332A5 (enExample
JP2020507332A (ja
Inventor
リュベナウ ハインツ
Original Assignee
バクシム アクチェンゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バクシム アクチェンゲゼルシャフト filed Critical バクシム アクチェンゲゼルシャフト
Publication of JP2020507332A publication Critical patent/JP2020507332A/ja
Publication of JP2020507332A5 publication Critical patent/JP2020507332A5/ja
Priority to JP2023133276A priority Critical patent/JP2023160838A/ja
Application granted granted Critical
Publication of JP7712060B2 publication Critical patent/JP7712060B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4225—Growth factors
    • A61K40/423—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001109—Vascular endothelial growth factor receptors [VEGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00113—Growth factors
    • A61K39/001135—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A61K39/001153—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001166—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A61K39/001168—Mesothelin [MSLN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00118—Cancer antigens from embryonic or fetal origin
    • A61K39/001182—Carcinoembryonic antigen [CEA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/36—Adaptation or attenuation of cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Vascular Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2019544614A 2017-02-17 2018-02-16 新規ｖｅｇｆｒ－２ターゲット免疫療法アプローチ Active JP7712060B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023133276A JP2023160838A (ja) 2017-02-17 2023-08-18 新規ｖｅｇｆｒ－２ターゲット免疫療法アプローチ

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17156718.3 2017-02-17
EP17156718 2017-02-17
PCT/EP2018/053918 WO2018149982A1 (en) 2017-02-17 2018-02-16 Novel vegfr-2 targeting immunotherapy approach

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023133276A Division JP2023160838A (ja) 2017-02-17 2023-08-18 新規ｖｅｇｆｒ－２ターゲット免疫療法アプローチ

Publications (3)

Publication Number Publication Date
JP2020507332A JP2020507332A (ja) 2020-03-12
JP2020507332A5 JP2020507332A5 (enExample) 2021-03-25
JP7712060B2 true JP7712060B2 (ja) 2025-07-23

Family

ID=58094260

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019544614A Active JP7712060B2 (ja) 2017-02-17 2018-02-16 新規ｖｅｇｆｒ－２ターゲット免疫療法アプローチ
JP2023133276A Withdrawn JP2023160838A (ja) 2017-02-17 2023-08-18 新規ｖｅｇｆｒ－２ターゲット免疫療法アプローチ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023133276A Withdrawn JP2023160838A (ja) 2017-02-17 2023-08-18 新規ｖｅｇｆｒ－２ターゲット免疫療法アプローチ

Country Status (13)

Country Link
US (1) US10980868B2 (enExample)
EP (1) EP3583200A1 (enExample)
JP (2) JP7712060B2 (enExample)
KR (2) KR20190117603A (enExample)
CN (1) CN110291187A (enExample)
AU (1) AU2018222777B9 (enExample)
BR (1) BR112019016925A2 (enExample)
CA (1) CA3050833A1 (enExample)
IL (1) IL268186A (enExample)
MX (1) MX2019009724A (enExample)
RU (1) RU2019125436A (enExample)
SG (1) SG11201907391SA (enExample)
WO (1) WO2018149982A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3310379T3 (pl) * 2015-06-18 2020-03-31 Vaximm Ag Szczepionka dna wycelowana w vegfr-2 do terapii skojarzonej
CA3109430A1 (en) * 2018-09-05 2020-03-12 Vaximm Ag Neoantigen targeting dna vaccine for combination therapy
CN113527509B (zh) * 2020-04-17 2023-09-26 深圳华大生命科学研究院 含有重组蛋白和保护蛋白的复合物在治疗肺鳞癌中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016202459A1 (en) 2015-06-18 2016-12-22 Vaximm Ag Vegfr-2 targeting dna vaccine for combination therapy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO337687B1 (no) 2011-07-08 2016-06-06 Norsk Elektro Optikk As Hyperspektralt kamera og metode for å ta opp hyperspektrale data
US9493738B2 (en) * 2011-12-22 2016-11-15 Vaximm Ag Method for producing high yield attenuated Salmonella strains
EP3603664A1 (en) 2012-07-05 2020-02-05 Vaximm AG Dna vaccine for use in pancreatic cancer patients
ES2675020T3 (es) * 2013-04-25 2018-07-05 Vaximm Ag Vectores basados en Salmonella para inmunoterapia del cáncer dirigida al gen WT1 del tumor de Wilms
SG11201604911VA (en) * 2013-12-18 2016-07-28 Vaximm Gmbh Novel msln targeting dna vaccine for cancer immunotherapy
WO2015142875A1 (en) * 2014-03-17 2015-09-24 The Trustees Of The University Of Pennsylvania Compositions and methods using modified salmonella
BR112019000657A2 (pt) 2016-07-13 2019-04-24 Vaximm Ag método para produzir uma vacina de dna para imunoterapia de câncer e vacina de dna

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016202459A1 (en) 2015-06-18 2016-12-22 Vaximm Ag Vegfr-2 targeting dna vaccine for combination therapy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Oncotarget, 2015, Vol.6, No.31, pp.31050-31068

Also Published As

Publication number Publication date
JP2023160838A (ja) 2023-11-02
BR112019016925A2 (pt) 2020-05-26
KR20190117603A (ko) 2019-10-16
CN110291187A (zh) 2019-09-27
US20200038496A1 (en) 2020-02-06
EP3583200A1 (en) 2019-12-25
JP2020507332A (ja) 2020-03-12
AU2018222777B2 (en) 2024-02-01
IL268186A (en) 2019-09-26
AU2018222777B9 (en) 2024-02-22
US10980868B2 (en) 2021-04-20
WO2018149982A1 (en) 2018-08-23
SG11201907391SA (en) 2019-09-27
RU2019125436A (ru) 2021-03-17
KR20240170928A (ko) 2024-12-05
CA3050833A1 (en) 2018-08-23
MX2019009724A (es) 2019-10-07
AU2018222777A1 (en) 2019-08-08

Similar Documents

Publication Publication Date Title
US10293037B2 (en) DNA vaccine for use in pancreatic cancer patients
US20220273782A1 (en) Novel PD-L1 Targeting DNA Vaccine for Cancer Immunotherapy
JP2016518835A (ja) ウィルムス腫瘍遺伝子ｗｔ１を標的とする癌免疫療法用のサルモネラベースのベクター
JP2023160838A (ja) 新規ｖｅｇｆｒ－２ターゲット免疫療法アプローチ
US20210077605A1 (en) Vegfr-2 targeting dna vaccine for combination therapy
US20230158133A1 (en) Wt1 targeting dna vaccine for combination therapy
AU2021208400A1 (en) Salmonella-based DNA vaccines in combination with an antibiotic

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210209

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210209

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220118

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220418

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220830

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230116

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230418

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230825

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250710

R150 Certificate of patent or registration of utility model

Ref document number: 7712060

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150